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Abstract
Background: Malignancy is a complex process resulting 
from different changes such as extracellular matrix (ECM) re-
modeling and stiffness. One of the important enzymes that 
contribute to ECM remodeling is lysyl oxidase (Lox) that is 
overexpressed in different types of human cancers. Because 
of the high prevalence and poor survival of gastrointestinal 
(GI) malignancies in this review, we discuss the association 
between Lox activity and the progression of GI cancers. Lox 
proteins are a group of extracellular enzymes that catalyzed 
the cross-linking of collagen and elastin, so they have impor-
tant roles in the control of structure and homeostasis of ECM. 
Abnormal activation and expression of the Lox family of pro-
teins lead to changes in the ECM toward increased rigidity 
and fibrosis. Stiffness of ECM can contribute to the patho-
genesis of cancers. Summary: Dysregulation of Lox expres-
sion is a factor in both fibrotic diseases and cancer. ECM stiff-
ness by Lox overactivity creates a physical barrier against in-
tratumoral concentration of chemotherapeutic drugs and 
facilitates cancer inflammation, angiogenesis, and metasta-
sis. Key Message: Because of the roles of Lox in GI cancers, 
development targeting Lox protein isotypes may be an ap-
propriate strategy for treatment of GI cancers and improve-
ment in survival of patients. © 2020 The Author(s)
Published by S. Karger AG, Basel
Introduction
Carcinogenesis is a complex process and is the conse-
quence of various modifications such as extracellular ma-
trix (ECM) remodeling [1]. ECM is a noncellular compo-
nent including proteoglycans, fibronectin, and fibers 
such as collagen and elastin. ECM provides mechanical 
and structural support for cells and tissues [1]. Lysyl oxi-
dase (Lox) is a copper-dependent enzyme that is encoded 
by the Lox gene [2]. Lox and Lox-like 1–4 are members of 
the Lox protein family [3] that are expressed in different 
cell types including endothelial cells, smooth muscle cells, 
and other cell types in various organs such as the gastro-
intestinal (GI) tract [4–6]. Lox catalyzes the cross-linking 
of collagen and elastin in the ECM through deamination 
of lysine and hydroxylysine residues to aldehyde, so they 
play an important role in control of structure, tensile 
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strength, and homeostasis of ECM that is essential in nor-
mal functioning of connective tissues and tissue remodel-
ing [7, 8]. Recent studies have reported that dysregulation 
of Lox activity leads to an increase in ECM remodeling as 
a result of cross-link density of collagen and elastin to de-
velop ECM fibrosis. This disturbs the cell polarity, pro-
motes cell proliferation, and contributes to cancer forma-
tion and progression. Lox mRNA and protein are highly 
expressed in GI organs such as the liver [9], GI submu-
cosa [10], and pancreas [11] during fibrosis. Stromal cells 
around the tumor microenvironment also express high 
level of Lox that has critical roles in tumor invasion and 
metastasis [12, 13]. Collagen is one of the major targets 
for Lox and is a major constituent of organ fibrosis and 
tumor stroma. The amount and distribution of collagen 
in the ECM are an important factor for the behavior of 
cancer cells including the conversion of signal transduc-
tion pathways, receptors, and transcriptional factors. In 
this review, we summarize the roles of Lox in GI malig-
nancies focusing on ECM changes, angiogenesis, and in-
flammation associated with cancer development.
Lox Roles in ECM Stiffness for Cancer Progression
The ECM that surrounds cells is an important regula-
tor for normal cellular and tissue function. The ECM is 
composed of water, fibrous proteins, minerals, and pro-
teoglycans that are secreted by resident cells. Homeosta-
sis of the ECM is important for biological processes such 
as wound healing, embryonic development, and normal 
organ function, and dysregulation of ECM changes the 
behavior of cells and tissues toward pathological condi-
tions. Fibrotic diseases, tumorigenesis, and tumor cell 
metastasis are affected by ECM dysregulation [14]. Ab-
normal expression of Lox mRNA and protein has been 
reported in wide range of disorders related to ECM such 
as several malignancies [15]. Tumor microenvironment 
stiffness and fibrosis change it to a metastatic site and 
contribute tumor cells to colonize distant organs. Cox et 
al. [16] have reported that induction of fibrosis in the 
liver increases the ability of breast cancer cells to migrate 
and metastasis to the liver. In addition, stiffness of the 
ECM by Lox overactivity changes integrin signaling to 
modulate cell behavior. Integrins are an important mem-
ber of adhesion molecules that provide a link between 
cells and ECM. Integrins are cell sensors that distribute 
information from outside to inside the cells; therefore, 
changes in the ECM are detected by integrins to regulate 
signaling pathways [17]. In pathological process such as 
malignancies, Lox through induction of collagen cross-
linking leads to ECM stiffness and a change in the integ-
rin signaling pathways that contribute tumor cell-ECM 
interactions to promote adhesions and cancer cell metas-
tasis [18, 19]. Recent studies have demonstrated that the 
stiffness of tumor microenvironment upregulates phos-
phatidylinositide 3-kinase (PI3K) signaling activity to 
promote tumor cell invasion and metastasis [20]. One of 
the major molecules affected by Lox is collagen I (Col I). 
Studies have showed that there is a close correlation be-
tween Lox with Col I expression during cancer develop-
ment [21]. In addition, other studies have reported that 
Col I induces the proliferation and migration of tumor 
cells following the activation of integrin signaling [22]. 
Zhang et al. [23] have been demonstrated that Col I with 
upregulation of WNT/planar cell polarity signaling path-
way increases the invasion of colorectal cancer cells. 
They found that the expression of Col I was induced in 
colon cancer tissues and was associated with tumor pro-
gression [23]. An increase in the integrin signaling path-
ways such as PI3K and Jun NH2-terminal kinase (JNK) 
by Col I was reported in pancreatic carcinoma [11]. Ya-
manari et al. [24] reported that culture of pancreatic can-
cer cells in Col I gels containing media induces cancer 
cell differentiation more than the same cells cultured in 
matrigel. Menke et al. [25] showed that pancreatic cancer 
cells stimulate the migration, proliferation, and cell mor-
phogenetic transformation in response to Col I. Hypoxia 
is a master regulator for ECM stiffness. Lox induces Col 
I expression under hypoxic condition to make a colla-
gen-rich ECM. Transcription factor hypoxia-inducible 
factor-1α (HIF-1α) binds to the Lox promoter under hy-
poxic conditions. HIF-1α induces the expression of Lox 
mRNA in different types of cancer [26, 27]. Therefore, 
the HIF-1α/Lox/Col1 pathway leads to profibrotic mi-
croenvironment to facilitate tumor cell migration and 
metastasis. Moreover, Lox activity is involved in the ep-
ithelial-mesenchymal transition (EMT) that is essential 
for cancer cell metastasis. Various studies have reported 
that HIF-1α stimulates the EMT in vitro and induces ep-
ithelial cell migration by upregulation of Lox [13, 28]. 
Park et al. [29] have showed that positive Lox colorectal 
cells have more migratory potential compared with neg-
ative Lox cells. They showed that Lox promotes the EMT 
process and strongly declares the prometastatic role of 
Lox in colorectal cancer. These findings suggest impor-
tant roles of Lox as a mediator of tumor microenviron-
ment stiffness and as a modulator of fibrosis-enhanced 
metastatic growth and provide suggestions that Lox in-
hibitors may have potential to reduce cancer cell metas-
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tasis ability to increase patient’s survival. The potential 
effects of Lox activity in the ECM stiffness are summa-
rized in Figure 1.
Lox Roles in Angiogenesis
New blood vessel formation around tumors is an es-
sential stage for tumor metastasis; angiogenesis occurs to 
supply oxygen and nutrients to the tumor cells [30]. Mi-
croenvironment signals including hypoxia by HIF-1α in-
duce angiogenic factors such as vascular endothelial 
growth factor (VEGF) and can trigger angiogenesis [31]. 
Lox regulates some factors involved in ECM angiogene-
sis. Recent studies have reported the role of Lox in vas-
cular remodeling during angiogenesis and metastasis 
[32, 33]. Lox by the activation of the mitogen-activated 
protein kinase (MAPK) complex and phosphorylation of 
Akt and ERK protein signaling stimulates the expression 
of VEGF [34, 35]. Lox is also able to increase the expres-
sion of VEGF via transforming growth factor β (TGF-β) 
signaling activity. Lox is a target for TGF-β/Smad signal-
ing pathways; therefore, TGF-β upregulates the expres-
sion of VEGF through Lox [36]. TGF-β is an important 
profibrotic cytokine that induces ECM stiffness in fibrot-
ic conditions; moreover, TGF-β signaling has been 
shown to promote the production of Lox and collagens. 
TGF-β/Lox upregulates tumor microenvironment stiff-
ness and angiogenesis. Zhu et al. [34] have demonstrated 
that TGF-β can upregulate both Lox and VEGF in hepa-
tocellular carcinoma (HCC) cells and TGF-β/Lox leads 
to ECM stiffness by increasing the expression and cross-
linking of collagens, especially Col I. The tumor micro-
environment stiffness is stimulated by Col I via the inte-
grin β1 signaling pathway that leads to PI3K and Akt 
hyperphosphorylation to stimulate VEGF expression in 
HCC [34]. PI3K/Akt is one of the chief signaling path-


























Fig. 1. Overview of the complex interplay between the roles of Lox 
in tumor microenvironment rigidity and cancer development. Lox 
with increase in collagen fiber cross-linking and ECM rigidity up-
regulates integrin signaling pathways to increase tumor cell inva-
sive capacity. Moreover, Lox with activation of MAPK complex, 
phosphorylation of ERK and Akt, and stimulation of PDGFRβ in-
duces EMT, angiogenesis, and cancer development. Also, Lox ex-
pression can be induced by HIF-1α and TGF-β/Smad which leads 
to cancer progression. ECM, extracellular matrix; Lox, lysyl oxi-
dase; PDGFRβ, platelet-derived growth factor receptor beta; EMT, 
epithelial-mesenchymal transition; TGF-β, transforming growth 
factor β; Col, collagen; MAPK, mitogen-activated protein kinase.
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[37] have demonstrated that Lox increases the expres-
sion and cross-linking of Col IV and simulates the angio-
genic and metastatic process of HCC. There is a positive 
correlation between VEGF expression in tumors and tu-
mor microenvironment rigidity; on the other hand, in-
creased ECM stiffness via Lox/Col I facilitates angiogen-
esis. A recent study has reported that the Lox inhibitor 
β-aminoproprionitrile reduces VEGF expression and 
angiogenesis by suppressing the activation of MAPK 
complex and Akt [38]. Also, other studies have reported 
that Lox causes the induction of platelet-derived growth 
factor receptor beta (PDGFRβ) to stimulate the expres-
sion of VEGF. Baker et al. [39] have indicated that Lox 
with stimulation of PDGFRβ promotes Akt signaling 
pathways which leads to VEGF expression at both the 
mRNA and protein level in vitro. In next stage, they 
treated the cells with inhibitors of PDGFRβ or Akt-me-
diated signaling or inhibitors of angiogenesis; they found 
that these drugs abolished the Lox-mediated increases in 
VEGF expression. Clinical studies have shown that tar-
geting Lox reduced angiogenesis because Lox regulates 
several signaling networks. In summary, these data show 
that Lox, an ECM-modifying enzyme, has a key role in 
cancer angiogenesis in experimental and clinical studies 
related to GI malignancies. Potential effects of Lox activ-
ity are briefed in Figure 1.
Lox and Inflammation
Recent studies have reported that Lox activity mediates 
inflammation in tumor microenvironment which plays 
an essential role in cancer progression. Abnormality in the 
inflammatory responses in the ECM promotes the angio-
genic and metastatic processes associated with cancer 
cells. Several cytokines released in tumor microenviron-
ment by infiltrating lymphocytes, cancer-associated fibro-
blasts, and macrophages modulate metastatic cascade. 
The effects of tumor necrosis factor alpha (TNF-α) as an 
important inflammatory cytokine have been studied in 
different experimental animal models, and investigations 
show that anti-TNF drugs have potential to reduce metas-
tasis [40, 41]. Also, there is a strong association between 
inflammation and EMT to stimulate migration and me-
tastasis of tumor cells [42]. In addition, inflammation is 
able to increase angiogenesis. The level of interleukin 6 
(IL-6), an important inflammatory cytokine, is correlated 
with VEGF level in gastric and colorectal cancer [43, 44]. 
Inflammatory cytokines upregulate signaling pathways 
involved in the expression of angiogenic mediators; for 
example, IL-6 with phosphorylation of signal transducer 
and activator of transcription 3 (STAT3) promotes the ex-
pression of angiogenic mediators such as VEGF and HIF-
1α [45]. Dysregulation of inflammatory response induced 
by infiltrating lymphocytes and macrophages distributes 
high level of TGF-β in tumor microenvironment that con-
tributes proangiogenic effects [46]. Saito et al. [47] have 
showed a significant correlation between TGF-β and 
VEGF expression in gastric malignant tissues associated 
with poor prognosis in patients with advanced gastric car-
cinoma. Various studies demonstrated that the rigidity 
and fibrosis of ECM related to Lox overexpression lead to 
an increase in inflammation to promote tumor invasion. 
Jeong et al. [48] have showed that the Lox expression was 
connected with intratumoral and peritumoral inflamma-
tion; they found that the Lox expression was positively 
correlated with IL-4 expression and T-cell differentiation 
in fibrotic breast cancer. Fibrosis is associated with in-
flammation; therefore, ECM rigidity by overactivation of 
Lox promotes inflammation that leads to cancer develop-
ment. Few studies have demonstrated that Lox expression 
is regulated with inflammatory mediators under inflam-
mation condition. TGF-β1 as an inflammatory and profi-
brotic cytokine upregulates the mRNA and protein ex-
pression of Lox in fibroblasts. Voloshenyuk et al. [49] have 
indicated that TGF-β by Smad signaling pathways stimu-
lates the Lox expression; also, they found the MAPK com-
plex signaling pathway and PI3K/Akt activated by TGF-β 
are essential for upregulation of Lox. Interleukin 1β (IL-
1β), another important inflammatory mediator in acute 
inflammation, upregulates Lox expression in skin and 
lung fibroblasts [50, 51]. Moreover, TNF-α as a main in-
flammatory cytokine increases Lox expression through 
TGF-β/Smad and PI3K signaling pathways [52]. The roles 
of Lox in cancer progression are summarized in Table 1.
Clinical Studies in GI Malignancies Related to Lox 
Overactivity
Various clinical studies have investigated the associa-
tion between Lox expression and clinicopathogical fea-
tures, progression, and prognosis of GI cancers including 
colorectal, esophageal, HCC, gastric, and pancreatic car-
cinoma. In one study, 82 samples of colorectal tumors 
with healthy adjacent tissues were collected. The progno-
sis of patients in the following year was recorded. Also, 
the correlation between the Lox and HIF-1α expression 
was determined. It was found that the expression of Lox 
in tumors was significantly higher compared with the ad-
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jacent tissues and there was a positive correlation between 
HIF-1α and Lox expression. Patients with high-level ex-
pression of Lox have poorer prognosis. These results 
show the association between Lox and colorectal cancer 
progression [53]. In another study, 137 patients with 
colorectal adenocarcinoma were selected; the association 
between the expression of Lox with lymph node metasta-
sis and patient survival was evaluated. The results showed 
that there was a positive correlation between the levels of 
the expression of Lox with lymph node aggression and 
high rate of distant metastasis; also, there was a strong as-
sociation between Lox expression in tumors with poor 
survival of patients [54]. Kasashima et al. [55] have re-
ported an association between Lox expression and clini-
copathogical features of gastric cancer. In 544 patients, 
samples of gastric malignant tissues were collected. Pa-
tients with high Lox expression had significantly lower 
prognosis than those without Lox expression. Also, there 
was positive link between the expression of Lox and dis-
tance metastasis. Peng et al. [56] have shown that the ex-
pression of Lox in 184 gastric malignant tumors was sig-
nificantly different compared with peritumoral tissues. 
They found that the expression of Lox was higher in pa-
tients with advanced gastric cancer including distance 
lymph node metastasis and serosal invasion. Also, there 
was a positive correlation between Lox with Col IV ex-
pression and cancer progression. In addition, survival 
analysis indicated that patients with high-level expression 
of Lox had poor survival [56]. Furthermore, the associa-
tion between Lox expression and lymph node metastasis 
with overall survival was evaluated in patients with esoph-
ageal cancer. The protein expression of Lox was higher in 
esophageal squamous cell carcinoma than in normal 
esophageal tissues; also, the number of metastatic nodes 
and poor survival in patients were associated with high-
level expression of Lox in esophageal malignant tissues 
[57]. In another study with 148 tissues of patients with 
HCC, the expression of Lox in tissues was investigated 
simultaneously with clincopathologial features and over-
all survival in patients. They reported that there was a 
positive correlation between Lox expression in tumors 
and size of tumor and advanced grade of HCC; in addi-
tion, Lox had close relation with VEGF expression in 
HCC tissues and shorter survival [34]. These studies con-
tribute to this theory that Lox inhibitors may have strong 
potential to reduce cancer progression alone or in com-
bination with chemotherapy drugs against GI malignan-
cies.
Future Perspectives of Lox Inhibitors in Cancer 
Therapy
In this review, we have discussed the roles of Lox in 
ECM stiffness, angiogenesis, inflammation, and cancer 
progression. Dysregulation of Lox expression is a factor 
in both fibrotic diseases and cancer. ECM stiffness by Lox 
overactivity creates a physical barrier against intratumor-
al concentration of chemotherapeutic drugs. Therefore, 
Lox can be a molecular target for treatment of cancers. 
Benjamin et al. [58] have showed that enzymatic activity 
of Lox promotes PDAC chemoresistance in pancreatic 
cancer. They found that Lox activity reduces gemcitabine 
intratumoral dissemination; in addition, adjuvant gem-
Table 1. The roles of Lox in cancer progression
Lox effects
ECM dysregulation Lox overactivity in cancer leads to ECM dysregulation including ECM stiffness and fibrosis; these conditions 
lead to change in integrin signaling pathways, increase the cross-linking of collagens, and promote tumor cell 
invasion and metastasis
Angiogenesis Most important molecular mechanisms affected by Lox which induces angiogenesis include the following: 
promotion of the MAPK and PI3K/Akt signaling pathways to stimulate the expression of VEGF and increase 
in the TGF-β/Smad signaling upregulates the expression of VEGF to induce angiogenesis in tumors site
Inflammation Rigidity and fibrosis of ECM related to Lox overexpression lead to an increase in inflammation to promote 
tumor invasion. Also, inflammation and increase in the inflammatory cytokines around the tumor site incre-
ase the mRNA and protein expression of Lox. Inflammation and Lox increase each other around the tumors
ECM, extracellular matrix; Lox, lysyl oxidase; TGF-β, transforming growth factor β; MAPK, mitogen-activated protein kinase; VEGF, 
vascular endothelial growth factor.
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citabine benefit was decreased by the increase in collagen 
fiber organization as a result of Lox activity [58]. The first 
Lox2 humanized monoclonal antibody (simtuzumab) 
has recently been developed and has entered phase II clin-
ical trials for pancreatic cancer. A combination of simtu-
zumab with chemotherapy agent gemcitabine failed to 
increase survival of patients compared to gemcitabine 
alone [59]. Also, in another randomized, double-blinded 
clinical trial, the effects of simtuzumab in combination 
with FOLFIRI were used for the treatment of metastatic 
KRAS mutant colorectal cancer. The combination of sim-
tuzumab with FOLFIRI did not improve clinical out-
comes of patients [60]. These results suggest that target-
ing only 1 member of Lox family is probably to have no 
clinical benefit, and further studies are needed to develop 
more effective drugs to inhibit Lox family activities.
Conclusion
Our review has made a concept about the Lox activity 
mechanisms in facilitating cancer inflammation, angiogen-
esis, and metastasis. Control of ECM is essential for regulat-
ing many crucial cellular processes. ECM stiffness is a key 
factor for cancer development contributed by Lox activity. 
Lox overactivity upregulates different molecular signaling 
pathways associated with ECM rigidity and fibrosis. Be-
cause the association between Lox and cancer development 
can be a molecular target for anti-cancer treatment, novel 
therapeutic strategies in cancers with the target of Lox inhi-
bition open windows to decrease chemoresistance and can-
cer progression and increase overall survival of patients. 
Drug delivery with the goal of Lox isotope inhibition or 
combination of monoclonal antibodies against the Lox iso-
types with routine chemotherapy drugs may be effective in 
decreasing progression of GI malignancies. Recent studies 
have showed that targeting Lox isotype 1 has potential for 
inhibition of tumor progression and metastasis in colorec-
tal cancer. One study in California showed that a monoclo-
nal antibody (AB0023) against Lox isotype 2 was effective 
in primary or metastatic xenograft models of cancer. There-
fore, based on roles of Lox in pathogenesis of cancer, inhibi-
tion of the Lox activity and development of drugs to target 
Lox family may have therapeutic significance for treatment 
of GI tumors in the clinic to improve patient’s conditions, 
so more studies are required to confirm this conclusion.
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